<DOC>
	<DOCNO>NCT01738503</DOCNO>
	<brief_summary>This open-label study treatment seek opioid-dependent subject safety , tolerability , pharmacokinetics ( PK ) , efficacy marker , opioid receptor availability subcutaneous injection depot buprenorphine induction stabilization treatment seek subject onto Subutex .</brief_summary>
	<brief_title>Multiple Dose Pharmacokinetics Depot Buprenorphine Opioid-Dependent Subjects</brief_title>
	<detailed_description />
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Male female subject Agree take buprenorphine product administer current study throughout participation study Body mass index ( BMI ) &gt; 18.0 &lt; 33.0 kg/m Participants current diagnosis require chronic opioid treatment Participants history risk factor Torsades de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) ECG demonstrate Fridericia 's correct QT interval ( QTcF ) &gt; 450 msec male QTcF &gt; 470 female screen Abuse buprenorphine use buprenorphine within 14 day inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Opioid Dependence , Buprenorphine , Depot , SUBUTEX , RBP-6000</keyword>
</DOC>